Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-MCL-INTENSIVE-RDHAP-AUTOSCT |
| ID | IND-MCL-1L-INTENSIVE |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff |
| Diseases | DIS-MCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
STUB.
These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.
The consulted eviQ overview reports the MCL Younger time-to-treatment-failure endpoint. It must not be relabelled as progression-free survival or transferred automatically to a different conditioning regimen.
Endpoint terminology and conditioning scope only; not verification of the other response or survival estimates in this indication.
eviQ 1855 v3 Efficacy and conditioning caveat.
ALGO-MCL-1L - ALGO-MCL-1L